Emory University researchers have received approval from the Food and Drug Administration (FDA) to advance to the next phase of a landmark trial to treat patients with Amyotrophic Lateral Sclerosis (ALS) using human neural stem cells.
The Phase I trial, currently underway exclusively at Emory University, is designed to assess the safety of implanting neural stem cells into the spinal cord in up to 18 people with ALS and began in January 2010. The first 12 patients received neural stem cell transplants in the lumbar, or lower, region of the spinal cord. After reviewing safety data from these patients, the
A revolutionary stem cell procedure may be able to stop ALS, or Lou Gehrig‘s disease, in its tracks.
HealthFirst reporter Leslie Toldo shares the story of one of the few people who have had it done.
ALS is a deadly disease, with a quick and devastating decline. This could be the hope thousands of people have been waiting for.
Fifty-five-year-old Tom Elliott is not a quitter. He has ALS and fights to keep up with the daily routines of his life, even as the disease makes everything harder. “Brushing the teeth has become a real chore. Turning and rolling in bed to
39-year-old Ted Harada was diagnosed with ALS, also known as Lou Gehrig‘s disease. It’s one of the worst diagnoses anyone could get.
He and his doctors expected his health to have severely declined by now. But thanks to an experimental stem cell treatment, he has tossed his cane and is once again playing in the pool with his three kids (…)
Then his neurologist told him about an experiment at Emory University that was recruiting ALS patients to test a stem cell treatment.
The surgeons told Harada that injecting the stem cells into his spine likely would not help him personally, and
Image via Wikipedia
Treating a heart attack with the patients’ own bone marrow stem cells boosts blood flow within the heart and may help reduce long-term complications, a new U.S. study finds.
The study included 31 patients who underwent angioplasty and stent placement after a heart attack. Within one week of the attacks, 16 of the patients received infusions of their own bone marrow cells into the coronary artery in which a blockage had caused the event.
The 16 patients received different amounts of bone marrow stem cells — 5 million, 10 million and 15 million cells. The 15 patients in the
Emory University researchers are participating in a groundbreaking clinical trial to treat patients with amyotrophic lateral sclerosis (ALS) using human neural stem cells.
The Phase 1 trial, will assess the safety of stem cells, and the surgical procedures and devices required, for multiple injections of the cells directly into the spinal cord.
“This is the first U.S. clinical trial of stem cell injections into the spinal cord for the treatment of ALS,” says principal researcher Jonathan Glass, professor of neurology in the School of Medicin, and director of the Emory ALS Center. “Our main goal in this early phase is to